Column Group
One Letterman DriveSan Francisco, CA 94129-1492
Website: thecolumngroup.com
Firm Size
- Assets Under Management (AUM):$4.2 Billion
- Number of Funds:12
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Description
The Column Group is a venture capital firm based in San Francisco, California. They focus on investing in early-stage life science companies, particularly in the fields of drug discovery, pharmaceuticals, biotechnology, and bioinformatics. The firm was founded in 2007 by Peter Svennilson and Bob More in order to support innovative scientific research and development. They provide financial backing, strategic guidance, and access to a network of experts in order to assist their portfolio companies in achieving their goals. The Column Group has invested in numerous successful companies, helping them advance groundbreaking scientific discoveries and transform them into commercial products that benefit society.Latest News
Powered by
Jun 13, 2024: InduPro Announces $85 Million Series A Financing, Appoints Prakash Raman, Ph.D. as CEO to Advance Next-Generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Disea
Feb 27, 2024: SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates NGM, AA, HRT, KNTE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 27, 2024: SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AA, NGM, MDC, KAMN
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
Jan 23, 2024: Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing. The financing was led by Mirae Asset Capital Life Science, with participation from other new investors, Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb and Johnson & Johnson Innovation – JJDC, Inc., as well as all existing investors, including The Column Group, Atlas Venture, Droia Ventures, GV, EcoR1 Capital, AbbVie Ventures, The Mark Foundation for Cancer Research, Timefolio Capital (formerly known as NS Investment) and others. In conjunction with the financing, Naveen Krishnan , MD, MPhil, Managing Director of Mirae Asset Capital Life Science will join the Company's Board of Directors.
Jan 17, 2024: Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammat
Jan 03, 2024: Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease
Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company) along with new investors WTT Investment, Willett Advisors, and others. The funds will support clinical development of the company's lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.